Audited Supplier
Yes
Non-Customized
GMP, USP, BP
Adult
Powder
>96%
Dongcheng
Drum
China
3001901000
Product Description
[Drug Name]
Generic name: Enoxaparin sodium injection
Chinese pinyin: Yinuogansuna Zhusheye
(Active ingredients]
Chemical name: Enoxaparin sodium (Low-Molecular-Weight Heparin Sodium) Stmctural formula:
[indications]
Prophylaxis of venous thromboembolic disease (prevention ofblood clot formation in the veins), in particular those which may be associated with orthopedic or general surgery. Treatment of established deep vein thrombosis, with or without pulmonary embolism, clinical symptoms are not serious, not including pulmonary embolism requires smgery or thrombolytics treatment.
Treatment of unstable angina and non-Q-wave myocardial infarction, administered concurrendy with aspirin.
Prevention of thrombus formation in the extra-corporal circulation during hemodialysis.
[Strength] 0.2 ml: 2000 Axa IU; 0.4 ml: 4000 AxalU; 0.6 ml: 6000 Axa IU; 0.8 ml: 8000 Axa IU
[Dosage and Administration]
Enoxaparin sodium can be administered subcutaneously as a single daily iiyection of 150 Axa lU/kg. In patients with complicated thromboembolic disorders, a dose of 100 Axa lU/kg twice daily is recommended. In patients weighing more than 100 kg or less than 40 kg, the dose has not been evaluated. The eflHcacy of enoxaparin sodium may be slightly reduced in patients with weight greater than 100 kg. In patients weighing less than 40 kg, the risk of bleeding may increase. For these patients, special clinical monitoring is required.
[Shelflife] 24 months
Generic name: Enoxaparin sodium injection
Chinese pinyin: Yinuogansuna Zhusheye
(Active ingredients]
Chemical name: Enoxaparin sodium (Low-Molecular-Weight Heparin Sodium) Stmctural formula:
[indications]
Prophylaxis of venous thromboembolic disease (prevention ofblood clot formation in the veins), in particular those which may be associated with orthopedic or general surgery. Treatment of established deep vein thrombosis, with or without pulmonary embolism, clinical symptoms are not serious, not including pulmonary embolism requires smgery or thrombolytics treatment.
Treatment of unstable angina and non-Q-wave myocardial infarction, administered concurrendy with aspirin.
Prevention of thrombus formation in the extra-corporal circulation during hemodialysis.
[Strength] 0.2 ml: 2000 Axa IU; 0.4 ml: 4000 AxalU; 0.6 ml: 6000 Axa IU; 0.8 ml: 8000 Axa IU
[Dosage and Administration]
Enoxaparin sodium can be administered subcutaneously as a single daily iiyection of 150 Axa lU/kg. In patients with complicated thromboembolic disorders, a dose of 100 Axa lU/kg twice daily is recommended. In patients weighing more than 100 kg or less than 40 kg, the dose has not been evaluated. The eflHcacy of enoxaparin sodium may be slightly reduced in patients with weight greater than 100 kg. In patients weighing less than 40 kg, the risk of bleeding may increase. For these patients, special clinical monitoring is required.
[Shelflife] 24 months
